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viability of cells present in surgical samples of degenerate intervertebral
disc tissue.
Methods: The technique for live/dead differentiation of cells used in this
study utilises the ﬂuorescent probes chloromethyl ﬂuorescein diacetate
(CMFDA) and ethidium homodimer (EH). Samples of herniated discs were
obtained from patients undergoing routine discectomy and processed
within 2 hours of excision. A small piece of each sample, approximately
5mm2, was incubated in 1ml of 25mM CMFDA/2mM EH solution in the
dark for 2 hours at 37°C. The tissue was then blotted dry and snap frozen.
Cryosections were taken at various points throughout the thickness of the
tissue sample, mounted with Vectashield containing DAPI and visualised
with a ﬂuorescent microscope. Cell viability was analysed by counting
at least 200 cells from a minimum of ﬁve ﬁelds of view.
Results: To date 21 surgical disc samples from patients, aged 17–57 years,
have been examined. Preliminary results show that greater than 80%
of cells are alive after excision. Cells in these discs commonly occur
in clusters (approximately 54% of disc cells are clustered). Clustered
cells exhibited a higher proportion of live cells compared to single cells
within the same tissue section, e.g. 93% of clustered cells were viable
compared to 82% of single cells. Cell viability appeared consistent across
all locations of the disc samples. Dead cells, when they did occur, were
predominantly seen around the periphery of the disc sections which
may be derived from trauma during dissection.
Conclusions: In contrast to reports in the literature, these results indicate
that the viability of cells from the herniated disc may be adequate
to consider for utilising in biological therapies. Interestingly, a greater
proportion of clustered cells appear to be viable compared to single cells.
Additionally we plan to investigate whether there is any relationship
between cell viability and the pathology, duration of symptoms or age of
patient, as this may serve as an indicator of the suitability of degenerate
discs for cell therapy.
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Purpose: Biology offers several strategies for restoring the degenerating
disc, including the use of natural proteins that increase matrix
accumulation and assembly, enhance the number of disc cells, or in other
ways lead to restoration of the native healthy disc. This is the basis for
administering Orthokine-derived Autologous Conditioned Serum (ACS) a
new treatment method that not only supplies with a pharmaceutical
monosubstance but with nutrients, anti-inﬂammatory cytokines and
several growth factors.
When peripheral blood is withdrawn and incubated with etched glass
beads, leukocytes within the aspirate enrich the plasma with anti-
inﬂammatory cytokines, such as IL-1Ra, as well as growth factors,
including PDGF, FGF-2, TGFb, IGF and HGF. After centrifuging and ﬁltering,
the ACS is returned locally to the affected region. It has been used
successfully, by way of local injection, for the treatment of human and
equine osteoarthritis, after ACL-reconstructive surgery and radiculopathy
(see references).
Methods: A non-blinded, prospective study was conducted to evaluate
feasibility and efﬁcacy of ACS injections in patients suffering from lumbar
disc pain (veriﬁed by anamnesis and clinics, MRI scan and distension
tests, no relieve after 8 weeks of well conducted conservative treatment,
pain reduction less than 50% VAS, after periradicular inﬁltration
procedures). 19 patients had a discography and three intradiscal
injections of ACS once per week for three consecutive weeks and were
followed for six months. Outcome was measured by patient administered
outcome instruments (VAS, ODI).
Results: Patients with showed a clinically remarkable and signiﬁcant
reduction in pain and disability after the ACS injection series. Mean
improvement was 58% in VAS. 11 out of 19 patients reported at least
50% pain improvement. No serious side effects occurred. There were no
infections in this series.
Conclusions: Although, these results must be conﬁrmed in larger clinical
trails and with objective assessments like quantitative MRI scans, the use
of ACS in the intervertebral disc could be worthy of consideration given
its impressive safety record and rich mixture of growth factors, cytokine
antagonists, and, possibly, additional helpful agents.
Fig. 1. ACS Production 1.1–1.5. For the ACS preparation whole blood
is drawn using special syringes (Orthokine EOT Syringe, Orthogen,
Duesseldorf, Germany) with increased inner surface area (1). While
the blood is incubated for six to nine hours (2), peripheral blood
leukocytes reproducibly produce elevated amounts of endogenous anti-
inﬂammatory cytokines. Following centrifugation and extraction (3+4),
autologous conditioned cell free serum (ACS) is then portioned (5) and
either stored until needed at minus 18° Celsius or directly injected into
the affected disc, joint or spinal region of the patient.
Table 1. Cytokines and growth factors present in autologous conditioned
serum (ACS) produced using the 10ml Orthokine system.
Mean
IL-1Ra 2015 pg
IL-6 28.7 pg
IL-10 33.4 pg
FGF b 27 pg
VEGF 509 pg
HGF 1,339 pg
IGF1 117,209 pg
PDGG AB 39,026 ng
TFG b 97,939 ng
Abbr.: IL-1Ra = interleukin-1 receptor antagonist; IL-6 = interleukin-6;
IL-10 = interleukin-10; FGFb = ﬁbroblast growth factor-b; VEGF = vascular
endothelial growth factor, HGF = hepatocyte growth factor; IGF1= insulin-
likegrowth-factor-1; PDGF = platelet derived growth factor, TGF-b =
transforming growth-factor-b. There is no noticeable induction of the
proinﬂammatory IL-1b or TNF-a. Measurements from ELISA kits (R&D
Systems).
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Introduction: Supraspinatus tendon (SE) is an essential structure for
the proper function of rotator cuff and it is the most frequently tendon
affected in the case of rotator cuff tears. Common surgical procedures
to repair SE lesions are often unsatisfactory due to the inadequate
recovery. Regenerative medicine is one of the most promising techniques
to improve these treatments by taking advantage of the regenerative
potential of mesenchymal stem cells (MSCs).
The aim of this study was to evaluate, in an experimental rat model, the
effectiveness of recovery after surgical treatment using MSCs embedded
in collagen type I vehicles.
Methodology: A chronic rotator cuff tear model was developed detaching
at the insertion site the SE of adult Sprague-Dawley rats (9 months old),
n = 4.
One month post-injury, the tendon was sutured with a type I collagen
vehicle with or without MSCs. One million cells, previously obtained
from the femoral channel of age matched rats were embedded in type I
collagen gel (n = 4) or attached to type I collagen membranes (n =4). In
parallel, a control group was treated only with the vehicle type I collagen
gel (n = 4) or with type I collagen membrane (n =4), free of cells.
Recovery was evaluated for each specimen three months after injury
determining the biomechanical strength (Newtons, N) of the tendon-
humerus interface (Instron). The contralateral shoulder was used as a
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positive control and results are expressed in Newtons case shoulder less
Newtons control shoulder.
Results are expressed in median [percentil25 – percentil75], non-
parametric Mann-Whitney U test was used for statistical analysis. P
values were obtained for comparison between non-treated animals
(chronic rotator cuff tears model) and treated groups.
Results: Treatment was well tolerated in all cases, no adverse effects
were observed in treated animals.
Non-treated animals (rotator cuff tear model) showed a resistance of –
3.9N [−8.4–0.71]. A signiﬁcant improvement of resistance was observed
in treatment groups.
In the case of MSCs with collagen type I membranes the resistance was
4.8N [1.3–7.1] and 3.3N [−0.17–7.67] in their respective controls (type
I collagen membrane without cells). In the case of MSCs with type I
collagen gel the resistance was 11.3N [9.7–19.0] and 7.8N [−2.1–14.3] in
their controls (type I collagen gel without cells).
Conclusions: We have observed a signiﬁcant recovery after repairing SE
chronic lesions via the use of MSCs in the context of type I collagen
vehicles. This “injury-repair” animal model using allogeneic MSCs could
be extrapolated as an alternative surgery in rotator cuff tears in human
subjects.
Table 1
Change p-value
Non-treated animals −3.97 N [−8.40, 0.71]
MSCs + membrane 4.89 N [1.36, 7.08] p = 0.021
Membrane 3.30N [−0.17, 7.67] p = 0.027
MSCs + gel 11.35 N [9.77, 19.00] p = 0.021
Gel 7.81 N [2.10, 14.33] p = 0.021
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ENGINEERING AN OSTEOCHONDRAL COMPOSITE FOR THE TOTAL
JOINT RESURFACING
H. Mera, J.E. Dennis. Benaroya Res. Inst. at Virginia Mason, Seattle, WA,
USA
Purpose: This laboratory is developing methods to engineer clinical-
scale, scaffold-free, tissue engineered cartilage for joint repair, as an
alternative to metal-based joint prostheses. The purpose of this study
is to combine engineered cartilage sheets, human bone marrow derived
mesenchymal stem cells (hMSCs) and trabecular tantalum metal (TTM)
into a single construct and, thus, enable its integration into native bone.
Methods: Rabbit auricular chondrocytes were isolated and culture-
expanded in 10% FBS in DMEM (low glucose), and used at primary
to 4th passage. To fabricate scaffold-free cartilage sheets combined
with hMSCs, rabbit auricular chondrocytes were applied to a “Double-
Diffusion Bioreactor” at 1.8×106 cells/cm2 and, 1 or 3 days later, hMSCs
were added at 3.1×106cells/cm2. The reverse order of cell seeding was
also performed with hMSCs added ﬁrst, and chondrocytes applied 1
or 3 days later. The cell composites were cultured for 4 weeks in
serum-free DMEM (high glucose), containing of 1% ITS-premix, 10 nM
Dexamethasone, 50uM ascorbate-2-phosphate, 1% sodium pyruvate, 1%
non-essential amino acid, 1% glutamax, and 1% Penicillin/Streptomycin.
The medium was changed daily on the inside of the bioreactor and every
other day on the outside reservoir of the bioreactor. To test conditions for
integrating TTM with engineered cartilage, 1.0 cm disks of sterile, porous
TTM were applied on top of the engineered cartilage at days 2, 4, 6,
with or without hMSCs applied at day 2, and cultured for an additional
4 weeks under the same conditions as above. The tissues were ﬁxed with
10% formalin and embedded in parafﬁn alone, for in situ hybridization, or
in plastic for imaging both TTM metal and cellular components. Parafﬁn
sections were stained with safranin-O and Fast Green and plastic sections
were stained with toluidine-blue. In order to detect the human-derived
cells, Alu in situ hybridization to Alu sequences was performed using an
automated system (Vantana, Inc.).
Results: Histologic sections showed that hMSCs and chondrocytes
integrated well under all conditions studied (Figure 1). In situ
hybridization images (Figure 2) showed a thin region, 50–80 microns
thick, that contained Alu-positive cells, which corresponds to the
Fast Green positive/safranin O-negative regions in Figure 1. The cell
application order of chondrocyte-ﬁrst and hMSC-second gives a smoother
surface than of hMSC-ﬁrst and chondrocyte-second, which more closely
resembles the native articular surface. The toluidine blue-stained plastic
sections showed robust expression of a cartilage-like matrix in both
the cartilage-only samples and in the combined cartilage-MSC samples
(Figure 3). The MSC-containing constructs tended to stain more lightly
and were thicker than the cartilage-only samples, suggesting there is
cross-talk between the MSCs and chondrocytes. Integration of TTM with
engineered cartilage was seen in the all combinations except that of TTM
applied to chondrocytes at day 6 without MSCs (Figure 4).
